Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares

by · The Cerbat Gem

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the transaction, the chief executive officer owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. This trade represents a 3.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

  • On Thursday, June 25th, William Lewis sold 21,398 shares of Insmed stock. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36.
  • On Wednesday, June 3rd, William Lewis sold 7,605 shares of Insmed stock. The shares were sold at an average price of $102.27, for a total transaction of $777,763.35.
  • On Thursday, April 16th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03.

Insmed Stock Down 2.2%

INSM stock traded down $2.65 during trading on Friday, hitting $115.61. 2,931,490 shares of the stock traded hands, compared to its average volume of 4,102,796. The firm’s 50 day moving average is $107.21 and its two-hundred day moving average is $138.27. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The stock has a market cap of $25.06 billion, a price-to-earnings ratio of -20.11 and a beta of 0.78.

Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm’s revenue for the quarter was up 229.7% on a year-over-year basis. During the same period in the previous year, the business earned ($1.42) EPS. On average, sell-side analysts anticipate that Insmed, Inc. will post -2.55 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on INSM shares. Wells Fargo & Company dropped their price target on Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Morgan Stanley raised shares of Insmed from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $166.00 to $212.00 in a report on Monday, March 30th. Truist Financial cut their target price on shares of Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Roth Capital reiterated a “buy” rating on shares of Insmed in a research report on Monday, June 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $211.00.

Get Our Latest Analysis on INSM

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC increased its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Insmed by 10.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 69 shares during the period. ORG Partners LLC boosted its position in shares of Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares during the period. Private Advisor Group LLC increased its stake in shares of Insmed by 1.8% in the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock worth $777,000 after purchasing an additional 82 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its stake in shares of Insmed by 5.4% in the first quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 98 shares in the last quarter.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Featured Articles